V. Buoro

Platinum-Based Chemotherapy in Older Patients with Non-Small Cell Lung Cancer: What to Expect in the Real World

G. Fasola, F. Puglisi, M. Macerelli, 2020, Drugs & Aging.

Novel antiangiogenic drugs for the management of breast cancer: new approaches for an old issue?

G. Aprile, M. Mansutti, C. Bozza, 2015, Expert review of clinical pharmacology.

KRAS and ERBB-family genetic alterations affect response to PD-1 inhibitors in metastatic nonsquamous NSCLC

M. Ferracin, M. Negrini, G. Fasola, 2019, Therapeutic advances in medical oncology.

Clinical Features and Progression Pattern of Acquired T790M-positive Compared With T790M-negative EGFR Mutant Non-small-cell Lung Cancer: Catching Tumor and Clinical Heterogeneity Over Time Through Liquid Biopsy.

A. Del Conte, S. Indraccolo, P. Conte, 2019, Clinical lung cancer.

Sarcopenia in gastric cancer: when the loss costs too much

G. Cardellino, A. Casadei‐Gardini, R. Caccialanza, 2017, Gastric Cancer.

Defining a prognostic score based on O6-methylguanine-DNA methyltransferase cut-off methylation level determined by pyrosequencing in patients with glioblastoma multiforme

G. Fasola, F. Puglisi, M. Isola, 2018, Journal of Neuro-Oncology.

Determinants of Last‐line Treatment in Metastatic Breast Cancer

G. Fasola, F. Puglisi, E. De Carlo, 2017, Clinical breast cancer.